Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst Says
Portfolio Pulse from Vandana Singh
Needham has initiated coverage on Immunocore Holdings Plc (NASDAQ:IMCR) with a Buy rating and a price target of $75. The company's product, Kimmtrak, has made a significant entrance into the market for the treatment of metastatic uveal melanoma. The primary source of value for Immunocore is its IMC-F106C program, which is poised to tap into a market of approximately 150,000 patients across various indications. Needham estimates potential sales of $1.3 billion by 2035 for IMC-F106C.
September 13, 2023 | 6:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham has initiated coverage on Immunocore with a Buy rating and a price target of $75. The company's IMC-F106C program is expected to generate significant revenue.
The positive coverage from Needham, along with the high price target, indicates strong confidence in Immunocore's potential. The company's IMC-F106C program is expected to tap into a large market, which could lead to significant revenue and potentially boost the company's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100